These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Crushing deutetrabenazine for treatment of tardive dyskinesia in a patient with severe orofacial symptoms: A case report. Wietholter JP; Sizemore J; Piechowski K Am J Health Syst Pharm; 2020 Sep; 77(18):1477-1481. PubMed ID: 32761113 [TBL] [Abstract][Full Text] [Related]
27. Relapse of tardive dyskinesia due to reduction in clozapine dose. Shrivastava M; Solanke B; Dakhale G; Somani A; Waradkar P Indian J Pharmacol; 2009 Aug; 41(4):201-2. PubMed ID: 20523875 [TBL] [Abstract][Full Text] [Related]
28. Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. Bergman H; Walker DM; Nikolakopoulou A; Soares-Weiser K; Adams CE Health Technol Assess; 2017 Aug; 21(43):1-218. PubMed ID: 28812541 [TBL] [Abstract][Full Text] [Related]
29. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Bhidayasiri R; Fahn S; Weiner WJ; Gronseth GS; Sullivan KL; Zesiewicz TA; Neurology; 2013 Jul; 81(5):463-9. PubMed ID: 23897874 [TBL] [Abstract][Full Text] [Related]
31. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Margolese HC; Chouinard G; Kolivakis TT; Beauclair L; Miller R; Annable L Can J Psychiatry; 2005 Oct; 50(11):703-14. PubMed ID: 16363464 [TBL] [Abstract][Full Text] [Related]
38. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. Meyer JM CNS Spectr; 2016 Dec; 21(S1):13-24. PubMed ID: 28044943 [TBL] [Abstract][Full Text] [Related]
39. Clinical risk factors for the development of tardive dyskinesia. Solmi M; Pigato G; Kane JM; Correll CU J Neurol Sci; 2018 Jun; 389():21-27. PubMed ID: 29439776 [TBL] [Abstract][Full Text] [Related]